From Theoretical Synergy to Clinical Supra-Additive Toxicity
- 20 March 2009
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 27 (9), 1359-1361
- https://doi.org/10.1200/jco.2008.20.8595
Abstract
No abstract availableThis publication has 25 references indexed in Scilit:
- Phase I Trial of Bevacizumab Plus Escalated Doses of Sunitinib in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2009
- Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206Journal of Clinical Oncology, 2008
- VEGF-targeted therapy: mechanisms of anti-tumour activityNature Reviews Cancer, 2008
- Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialThe Lancet, 2007
- Possible molecular mechanisms involved in the toxicity of angiogenesis inhibitionNature Reviews Cancer, 2007
- Sunitinib versus Interferon Alfa in Metastatic Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Targeted Therapy for Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2006
- The role of neuropilins in cancerMolecular Cancer Therapeutics, 2006
- Neutralization of Circulating Vascular Endothelial Growth Factor (VEGF) by Anti-VEGF Antibodies and Soluble VEGF Receptor 1 (sFlt-1) Induces ProteinuriaJournal of Biological Chemistry, 2003